Dr Reddys Laboratories
Dr Reddy’s Laboratories, commonly referred to as Dr Reddy’s, is a prominent Indian pharmaceutical preparation manufacturer headquartered in Hyderabad, India. Established in 1984, the company has grown to become a key player in the global pharmaceutical industry, with a strong presence across North America, Europe, and emerging markets.
Specialising in the development and production of generic medicines, active pharmaceutical ingredients (APIs), and biosimilars, Dr Reddy’s is recognised for its commitment to quality and innovation. Its diverse portfolio includes treatments for various therapeutic areas, such as oncology, cardiology, and central nervous system disorders. With a reputation for reliability and a focus on research-driven solutions, Dr Reddy’s has secured a notable position within the pharmaceutical manufacturing sector worldwide.
+53 vs industry average
Dr Reddys Laboratories’s score of 91 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Dr Reddys Laboratories?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 100% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Dr Reddys Laboratories's reported carbon emissions
Dr Reddy's Laboratories, a pharmaceutical preparation manufacturer headquartered in India, has reported its carbon emissions across Scopes 1, 2, and 3 for several years. For the most recent reporting year (2025), total global emissions were approximately 1.186 billion kg CO2e, comprising Scope 1 emissions of about 142.8 million kg CO2e, Scope 2 emissions of approximately 291 million kg CO2e, and Scope 3 emissions totalling around 845.8 million kg CO2e.
In the preceding year (2024), total global emissions stood at approximately 1.164 billion kg CO2e, with Scope 1 at around 189.5 million kg CO2e, Scope 2 at approximately 114.7 million kg CO2e, and Scope 3 at about 867 million kg CO2e.
Looking at earlier periods, the company reported total global emissions of approximately 1.273 billion kg CO2e in 2023 (reporting year 2024), with Scope 1 at 214.3 million kg CO2e, Scope 2 at approximately 137.6 million kg CO2e, and Scope 3 at about 921.1 million kg CO2e. In 2022 (reporting year 2023), total global emissions were around 1.389 billion kg CO2e, with Scope 1 emissions at approximately 302.5 million kg CO2e, Scope 2 at about 166.2 million kg CO2e, and Scope 3 at roughly 920.6 million kg CO2e. For 2021 (reporting year 2023), total global emissions were approximately 1.009 billion kg CO2e, including Scope 1 at 349.9 million kg CO2e and Scope 2 at approximately 177.5 million kg CO2e, with Scope 3 at about 471.6 million kg CO2e.
Dr Reddy's Laboratories has established several significant climate commitments. The company aims for 100% renewable power by 2030. Furthermore, it has set ambitious Science Based Targets initiative (SBTi) goals:
- A commitment to reduce Scope 1 and 2 GHG emissions by 50.2% per million USD revenue by FY2031 from an FY2021 base year. This is equivalent to a 25% absolute reduction.
- A commitment to reduce absolute Scope 3 GHG emissions by 12.3% by FY2031 from an FY2021 base year.
- More recently, Dr. Reddy's Laboratories Ltd. has committed to reducing absolute Scope 1 and 2 GHG emissions by 80.0% by FY2030 from a FY2023 base year.
- A long-term commitment to achieve net-zero greenhouse gas emissions across the value chain by FY2045. This includes a commitment to reduce absolute Scope 1 and 2 GHG emissions by 90.0% by FY2045 from a FY2023 base year, and absolute Scope 3 GHG emissions by 90.0% within the same timeframe.
These targets align with keeping global warming to Well-below 2°C and even the more ambitious 1.5°C scenario for certain commitments. The company's reporting covers all scopes, although there are noted missing data points for "purchased goods and services" within Scope 3 for some reporting periods.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Dr Reddys Laboratories’s Climate Goals (2030 & 2050)
2 goals2030
100% Renewable Power By 2030,
100% Renewable Power By 2030,
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Dr Reddys Laboratories
Frequently asked questions
Common questions about Dr Reddys Laboratories’s sustainability data and climate commitments
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project